[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580356":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":44,"locations":51,"responsibleParty":232,"collaborators":11,"id":234,"slug":235,"hasResults":236,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":11,"eligibilityCriteria":240,"healthyVolunteers":236,"sex":241,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":11,"studyType":247,"phases":248,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":268},{"fullName":5,"class":6},"Zomagen Biosciences Ltd.","INDUSTRY",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A","EXPERIMENTAL",null,[13],"Drug: VTX2735",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort B Treatment Group B1",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort B Treatment Group B2",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Cohort C Treatment Group C1",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort C Treatment Group C2",[13],[27,32,35,38,41],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","VTX2735","Dose A, Daily",[9],{"type":28,"name":29,"description":33,"armGroupLabels":34,"otherNames":11},"Dose B, Daily",[9,15,21,24],{"type":28,"name":29,"description":36,"armGroupLabels":37,"otherNames":11},"Dose C, Daily",[18],{"type":28,"name":29,"description":39,"armGroupLabels":40,"otherNames":11},"Dose D, Daily",[21],{"type":28,"name":29,"description":42,"armGroupLabels":43,"otherNames":11},"Dose E, Daily",[24],[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Ventyx Clinical Trial Contact","CONTACT","888-411-5176","ext 108","ClinicalTrials@ventyxbio.com",[52,66,77,87,97,106,116,126,136,145,155,165,171,181,191,201,210,220],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":11},"Local Site #840012","WITHDRAWN","Tucson","Arizona","85718","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-110.92648,32.22174,{"lat":64,"lon":63},{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":58,"countryCode":59,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"Local Site #840014","RECRUITING","Orange","California","92868",{"type":61,"coordinates":73},[74,75],-117.85311,33.78779,{"lat":75,"lon":74},{"facility":78,"status":68,"city":79,"state":80,"zip":81,"country":58,"countryCode":59,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"Local Site #840016","Saint Augustine","Florida","32086",{"type":61,"coordinates":83},[84,85],-81.31452,29.89469,{"lat":85,"lon":84},{"facility":88,"status":68,"city":89,"state":90,"zip":91,"country":58,"countryCode":59,"cosmosGeoPoint":92,"geoPoint":96,"contacts":11},"Local Site #840008","Chicago","Illinois","60611",{"type":61,"coordinates":93},[94,95],-87.65005,41.85003,{"lat":95,"lon":94},{"facility":98,"status":54,"city":99,"state":90,"zip":100,"country":58,"countryCode":59,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Local Site #840002","Park Ridge","60068",{"type":61,"coordinates":102},[103,104],-87.84062,42.01114,{"lat":104,"lon":103},{"facility":107,"status":54,"city":108,"state":109,"zip":110,"country":58,"countryCode":59,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"Local Site #840011","Owensboro","Kentucky","42303",{"type":61,"coordinates":112},[113,114],-87.11333,37.77422,{"lat":114,"lon":113},{"facility":117,"status":68,"city":118,"state":119,"zip":120,"country":58,"countryCode":59,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Local Site #840010","Boston","Massachusetts","02114",{"type":61,"coordinates":122},[123,124],-71.05977,42.35843,{"lat":124,"lon":123},{"facility":127,"status":68,"city":128,"state":129,"zip":130,"country":58,"countryCode":59,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Local Site #840005","Rochester","Minnesota","55905",{"type":61,"coordinates":132},[133,134],-92.4699,44.02163,{"lat":134,"lon":133},{"facility":137,"status":68,"city":138,"state":138,"zip":139,"country":58,"countryCode":59,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"Local Site #840020","New York","10032",{"type":61,"coordinates":141},[142,143],-74.00597,40.71427,{"lat":143,"lon":142},{"facility":146,"status":68,"city":147,"state":148,"zip":149,"country":58,"countryCode":59,"cosmosGeoPoint":150,"geoPoint":154,"contacts":11},"Local Site #840017","Cleveland","Ohio","44195",{"type":61,"coordinates":151},[152,153],-81.69541,41.4995,{"lat":153,"lon":152},{"facility":156,"status":68,"city":157,"state":158,"zip":159,"country":58,"countryCode":59,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"Local Site #840019","Houston","Texas","77030",{"type":61,"coordinates":161},[162,163],-95.36327,29.76328,{"lat":163,"lon":162},{"facility":166,"status":68,"city":157,"state":158,"zip":167,"country":58,"countryCode":59,"cosmosGeoPoint":168,"geoPoint":170,"contacts":11},"Local Site #840001","77034",{"type":61,"coordinates":169},[162,163],{"lat":163,"lon":162},{"facility":172,"status":68,"city":173,"state":174,"zip":175,"country":58,"countryCode":59,"cosmosGeoPoint":176,"geoPoint":180,"contacts":11},"Local Site #840013","Salt Lake City","Utah","84132",{"type":61,"coordinates":177},[178,179],-111.89105,40.76078,{"lat":179,"lon":178},{"facility":182,"status":68,"city":183,"state":184,"zip":185,"country":58,"countryCode":59,"cosmosGeoPoint":186,"geoPoint":190,"contacts":11},"Local Site #840022","Burlington","Vermont","05401",{"type":61,"coordinates":187},[188,189],-73.21207,44.47588,{"lat":189,"lon":188},{"facility":192,"status":68,"city":193,"state":194,"zip":195,"country":58,"countryCode":59,"cosmosGeoPoint":196,"geoPoint":200,"contacts":11},"Local Site #840018","Charlottesville","Virginia","22908",{"type":61,"coordinates":197},[198,199],-78.47668,38.02931,{"lat":199,"lon":198},{"facility":202,"status":68,"city":203,"state":194,"zip":204,"country":58,"countryCode":59,"cosmosGeoPoint":205,"geoPoint":209,"contacts":11},"Local Site #840004","Richmond","23219",{"type":61,"coordinates":206},[207,208],-77.46026,37.55376,{"lat":208,"lon":207},{"facility":211,"status":68,"city":212,"state":213,"zip":214,"country":58,"countryCode":59,"cosmosGeoPoint":215,"geoPoint":219,"contacts":11},"Local Site #840021","Seattle","Washington","98105",{"type":61,"coordinates":216},[217,218],-122.33207,47.60621,{"lat":218,"lon":217},{"facility":221,"status":68,"city":222,"state":223,"zip":224,"country":225,"countryCode":226,"cosmosGeoPoint":227,"geoPoint":231,"contacts":11},"Local Site #840101","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":61,"coordinates":228},[229,230],-75.69812,45.41117,{"lat":230,"lon":229},{"type":233,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580356","phase-2-an-open-label-pilot-study-of-vtx2735-in-recurrent-pericarditis-100580356",false,"NCT06836232","An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis","A Phase 2a, Open-Label Pilot Study to Evaluate the Safety\u002FTolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis","Inclusion Criteria:\n\n* Participants are male or female ≥ 18 years up to ≤ 75 years of age.\n* Capable of giving signed informed consent and able to comply with the protocol\n* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event\n* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.\n* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg\u002FL must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)\n* Pericarditis pain score ≥ 4 based on the 11-point NRS.\n* Stable doses of NSAIDs, colchicine, and\u002For oral corticosteroids (if receiving these treatments)\n\nExclusion Criteria:\n\n* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.\n* History of clinically significant immunosuppressive disorder, autoimmune\u002Fautoinflammatory disorder, or primary or secondary immunodeficiency.\n* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.","ALL","18 Years","75 Years",{"count":245,"type":246},50,"ESTIMATED","INTERVENTIONAL",[249],"PHASE2","This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).\n\nCohort A will include approximately 10 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A\n* A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A\n* An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period\n\nCohort B will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C\n* A 14-day Follow-Up Period\n\nCohort C will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period",[252],"Recurrent Pericarditis",[254,255,252,29,256,257,258],"Ventyx","Zomagen","NLRP3 Inhibitor","NLRP3","Inflammasome","2026-05-20",{"date":261,"type":262},"2026-05-22","ACTUAL",{"date":264,"type":262},"2025-01-28",{"date":266,"type":246},"2027-10",{"name":5,"class":6},18]